BC Partners Takes Control Of Synthon
Executive Summary
Private-equity firm BC Partners has struck a deal to acquire a majority stake in Synthon International Holding.
You may also be interested in...
Pharmathen Eyes US Growth As Owner Announces Sale
With plans to drive continuous innovation in drug administration technology and further implement state-of-the-art production capabilities, Swiss-based private equity Partners Group has announced a deal to acquire long-acting injectables specialist Pharmathen.
Who’s Hired? IGBA Names IPA’s Jain As Chair
The International Generic and Biosimilar Medicines Association has named the IPA’s Sudarshan Jain as its new chair. While Celltrion’s chairman has stepped down, Coherus has added two members to its board of directors and Synthon has appointed a new CEO.
Fixing The UK Market: Government Must Move From ‘Transactional’ To ‘Strategic’ Approach
With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.